Short report: Relapse of visceral leishmaniasis after miltefosine treatment in a nepalese patient

American Journal of Tropical Medicine and Hygiene

Volumn 80, Issue 4, 2009, Pages 580-582

  Pandey, Basu Dev ^a   Pandey, Kishor ^b   Kaneko, Osamu ^c   Yanagi, Tetsuo ^c   Hirayama, Kenji ^c  

^a Sukraraj Tropical and Infectious Disease Hospital Kathmandu   (Nepal)

^b UNIVERSITY OF TOKYO   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBODY; MILTEFOSINE; MINICIRCLE DNA; RK39 ANTIBODY; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; DRUG DERIVATIVE; PHOSPHORYLCHOLINE;

ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; FEVER; HEPATOMEGALY; HUMAN; KINETOPLAST; LEISHMANIA DONOVANI; MALE; NEPAL; NUCLEOTIDE SEQUENCE; PARASITE IDENTIFICATION; POLYMERASE CHAIN REACTION; RELAPSE; SPLENOMEGALY; VISCERAL LEISHMANIASIS; WEIGHT REDUCTION; PATHOLOGY; RECURRENT DISEASE; TREATMENT FAILURE;

LEISHMANIA DONOVANI;

ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIASIS, VISCERAL; MALE; NEPAL; PHOSPHORYLCHOLINE; RECURRENCE; TREATMENT FAILURE; YOUNG ADULT;

EID: 65349157642     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2009.80.580     Document Type: Article

References (17)

1. World Health Organization, 2002. The World Health Report 2002. Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization.
2. Sundar S, Mondal D, Rijal S, Bhattacharya S, Ghalib H, Kroeger A, Boelaert M, Desjeux P, Richter-Airijoki H, Harms G, 2008. Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal: the challenges for diagnosis and treatment. Trop Med Int Health 13: 2-5.
3. Desjeux P, 2004. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27: 305-318.
4. Minister of Health Nepal, 2007. The Internal Assesment of Malaria, Kala-azar Control Activites 2004, 2005, 2006. Kathmandu, Nepal: Ministry of Health, Directorate of Health Service, Epidemiology and Disease Control Division.
5. World Health Organization, 1990. Control of the leishmaniases. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 793:1-158.
6. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S. 2005. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 5: 763-774.
7. Sundar S, Murray HW, 2005. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 83:394-395.
8. Pandey K, Pant S, Kanbara H, Shuaibu MN, Mallik AK, Pandey BD, Kaneko O. Yanagi T, 2008. Molecular detection of Leishmania parasites from whole bodies of sandflies collected in Nepal. Parasitol Res 103:293-297.
9. Karki P, Koirala S, Parija SC, Handsak SG, Das ML, 1998. A thirty day course of sodium stibogluconate for treatment of kala-azar in Nepal. Southeast Asian J Trop Med Public Health 29:154-158.
10. Rijal S, Chappuis F, Singh R, Bovier PA, Acharya P, Karki BM, Das ML, Desjeux P, Loutan L, Koirala S, 2003. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 97:350-354.
11. Sundar S, 2001. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6:849-854.
12. Seifert K, Matu S, Javier Perez-Victoria F, Castanys S, Gamarro F, Croft SL, 2003. Characterisation of Leishmania donovani pro- mastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 22:380-387.
13. Troya J, Casquero A, Refoyo E, Fernández-Guerrero ML, Górgolas M, 2008. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. Scand J Infect Dis 40:78-80.
14. Sindermann H, Engel KR, Fischer C, Bommer W. 2004. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 39:1520-1523.
15. Perez-Victoria FJ, Gamarro F, Ouellette M, Castanys S, 2003. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem 278:49965-49971.
16. Calvopina M, Gomez EA, Sindermann H, Cooper PJ, Hashiguchi Y, 2006. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. Am J Trop Med Hyg 75:1074-1077.
17. Zerpa O, Ulrich M, Blanco B, Polegre M, Avila A, Matos N, Mendoza I, Pratlong F, Ravel C, Convit J, 2007. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol 156:1328-1335.